title: Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
abstract: Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.
authors.affiliation: Institutul Oncologic Bucuresti, Romania.
authors.forename: Rodica
authors.initials: R
authors.lastname: Anghel
authors.forename: Alexander
authors.initials: A
authors.lastname: Bachmann
authors.forename: Meral
authors.initials: M
authors.lastname: Bekşac
authors.forename: Thomas
authors.initials: T
authors.lastname: Brodowicz
authors.forename: Jindřich
authors.initials: J
authors.lastname: Finek
authors.forename: Radko
authors.initials: R
authors.lastname: Komadina
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Krzemieniecki
authors.forename: Istvan
authors.initials: I
authors.lastname: Lang
authors.forename: Jozef
authors.initials: J
authors.lastname: Marencak
authors.forename: Roger
authors.initials: R
authors.lastname: von Moos
authors.forename: Martin
authors.initials: M
authors.lastname: Pecherstorfer
authors.forename: Tamara
authors.initials: T
authors.lastname: Rordorf
authors.forename: Damir
authors.initials: D
authors.lastname: Vrbanec
authors.forename: Christoph
authors.initials: C
authors.lastname: Zielinski
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000556:secondary*; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology*; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D038622:Internationality; D010166:Palliative Care / Q000379:methods*; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000069448:Denosumab; D000077211:Zoledronic Acid